Cargando…

Rise of the BQ.1.1.37 SARS-CoV-2 Sublineage, Italy

BQ.1.1 has dominated the Europe and Americas COVID-19 wave across the 2022–2023 winter, and further viral evolution is expected to escape the consolidating immune responses. We report here the emergence of the BQ.1.1.37 variant in Italy, peaking in January 2022 before suffering competition by XBB.1....

Descripción completa

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Spezia, Pietro Giorgio, Capria, Anna-Lisa, Gueli, Federico, McConnell, Scott, Novazzi, Federica, Pistello, Mauro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001149/ https://www.ncbi.nlm.nih.gov/pubmed/36900144 http://dx.doi.org/10.3390/diagnostics13051000

Ejemplares similares

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
por: Focosi, Daniele, et al.
Publicado: (2023)

Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman
por: Vatteroni, Maria Linda, et al.
Publicado: (2022)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

A rapid surge of the Omicron variant’s sublineages BQ.1/BQ.1.1: A matter of worry amid the crucial trajectory of the COVID-19 pandemic
por: Dhawan, Manish, et al.
Publicado: (2023)

Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of SARS-CoV-2 sublineages reported from local cases in mainland China (September 2022-January 2023) and surveillance of outbound passengers.
por: Focosi, Daniele, et al.
Publicado: (2023)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Cataract in the Capsule with Notes on 1,137 Consecutive Operations
por: Baird, R.
Publicado: (1914)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

Lack of neutralizing activity in nonconvalescent sera, regardless of ABO blood group and anti-A isoagglutinin titer
por: Focosi, Daniele, et al.
Publicado: (2021)

Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy
por: Maggi, Fabrizio, et al.
Publicado: (2021)

TTV and other anelloviruses: The astonishingly wide spread of a viral infection
por: Spezia, Pietro Giorgio, et al.
Publicado: (2023)

Emergence BQ.1 and BQ.1.1 as newly identified omicron subvariants: current scenario and future outlook – an update
por: Akash, Shopnil, et al.
Publicado: (2023)

1137 Epidemiology and Persistence of Human Rhinovirus Infections in Childcare
por: Martin, Emily T., et al.
Publicado: (2014)

Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes
por: Maggi, Fabrizio, et al.
Publicado: (2021)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

SARS-CoV-2 recombinant XN, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

Human Gyrovirus DNA in Human Blood, Italy
por: Maggi, Fabrizio, et al.
Publicado: (2012)

Plasma Torquetenovirus (TTV) microRNAs and severity of COVID-19
por: Stincarelli, Maria Alfreda, et al.
Publicado: (2022)

Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy
por: Novazzi, Federica, et al.
Publicado: (2021)

SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses
por: Mazzetti, Paola, et al.
Publicado: (2023)

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
por: Wang, Qian, et al.
Publicado: (2023)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Expansion of L452R-Positive SARS-CoV-2 Omicron Variant, Northern Lombardy, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

Detection of Torquetenovirus and Redondovirus DNA in Saliva Samples from SARS-CoV-2-Positive and -Negative Subjects
por: Spezia, Pietro Giorgio, et al.
Publicado: (2022)

Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?
por: Varghese, Ryan, et al.
Publicado: (2023)

SARS‐CoV‐2 B.1.1.7 reinfection after previous COVID‐19 in two immunocompetent Italian patients
por: Novazzi, Federica, et al.
Publicado: (2021)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
por: Amano, Masayuki, et al.
Publicado: (2023)

Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients
por: Maggi, Fabrizio, et al.
Publicado: (2018)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients
por: Dewald, Felix, et al.
Publicado: (2023)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
por: Zhu, Airu, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
por: Bellusci, Lorenza, et al.
Publicado: (2023)

PReS13-SPK-1137: New developments in our care & understanding of JIA
por: Beresford, MW
Publicado: (2013)

1137. Variability of Antibiotic Use in Neonatal Intensive Care Units in the United States
por: Dantuluri, Keerti, et al.
Publicado: (2019)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1cpbhm4bk6ontc7rtmep9aa9d9